

Niraparib hydrochloride

Catalog No: tcsc2282

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:

1038915-64-8

Formula:

C₁₉H₂₁CIN₄O

Pathway: Epigenetics;Cell Cycle/DNA Damage

Target:

PARP;PARP

Purity / Grade:

>98%

Solubility: 10 mM in DMSO

Alternative Names:

MK-4827 (hydrochloride)

Observed Molecular Weight: 356.85

Copyright 2021 Taiclone Biotech Corp.




Product Description

Niraparib hydrochloride (MK-4827 hydrochloride) is an excellent **PARP1** and **PARP2** inhibitor with **IC**₅₀ of 3.8 and 2.1 nM, respectively.

IC50 & Target: IC50: 3.8 nM (PARP1), 2.1 nM (PARP2)^[1]

In Vitro: Niraparib inhibits PARP activity with EC_{50} =4 nM and EC_{90} =45 nM in a whole cell assay. Niraparib inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC_{50} in the 10–100 nM range. Niraparib displays excellent PARP 1 and 2 inhibition with IC_{50} =3.8 and 2.1 nM, respectively, and in a whole cell assay^[1]. To validate that Niraparib inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μ M Niraparib for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells^[2].

In Vivo: Niraparib is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vd_{ss}=6.9 L/kg), long terminal half-life (t_{1/2}=3.4 h), and excellent bioavailability, $F = 65\%^{[1]}$. Niraparib enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.